Search results
Showing 31 to 45 of 711 results for diabet*
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.
Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.
View recommendations for MTG66Show all sections
UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.
Awaiting development [GID-TA10665] Expected publication date: TBC
Awaiting development [GID-TA10438] Expected publication date: TBC
Awaiting development [GID-TA10439] Expected publication date: TBC
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)
Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.
Neuropad for detecting preclinical diabetic peripheral neuropathy (MTG38)
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.
In development [GID-NG10256] Expected publication date: TBC
In development [GID-NG10336] Expected publication date: 04 December 2024
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261]
In development [GID-TA11297] Expected publication date: 08 May 2024
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making